துறை ஆஃப் இரைப்பை குடல் புற்றுநோயியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article
Share this article
HOUSTON, March 4, 2021 /PRNewswire/ DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced the treatment of the first patient in a Phase 1 dose-escalation and dose-expansion study of DNX-2440, an OX40 ligand encoding oncolytic adenovirus, in patients with resectable liver metastasis. Expression of OX40 ligand on the surface of tumor cells is expected to enhance anti-tumor immune responses by providing costimulatory signals to T cells within the tumor microenvironment.
We are excited to clinically explore the potential of one of our immunotherapy drug candidates, which is based on our proprietary adenovirus platform technology, in additional cancer indications, said Jeffrey Knapp, chief executive officer of DNAtrix. Our preclinical work with DNX-2440 has demonstrated that infection of human tumor cell lines with this agent leads to viral replication, high level expression of OX40 ligand o ....

United States , Sylvia Wheeler , Prnewswire Dnatrix , Daniela Anaya , Alexandra Santos , Jeffrey Knapp , Hepatobiliary Group , Source Dnatrix Inc , Mercury Fund , Department Of Gastrointestinal Oncology , Moffitt Cancer Center , Gastrointestinal Oncology , Rare Pediatric Disease , Morningside Ventures , Media Contacts , Health Care Amp Hospitals , Medical Pharmaceuticals , Clinical Trials Amp Medical Discoveries , ஒன்றுபட்டது மாநிலங்களில் , சில்வியா சக்கர வாகனம் , டேனீலா ஆநாயைய , அலெக்சாண்ட்ரா சாண்டோஸ் , ஜெஃப்ரி ந்யாப் , ஹெபடோபிலியரி குழு , பாதரசம் நிதி , துறை ஆஃப் இரைப்பை குடல் புற்றுநோயியல் ,